+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adrenocorticotropic Hormone Receptor "

Adrenocorticotropic Hormone Receptor - Pipeline Review, H2 2020 - Product Thumbnail Image

Adrenocorticotropic Hormone Receptor - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 62 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

The Adrenocorticotropic Hormone Receptor (ACTHR) is a G-protein coupled receptor (GPCR) that is involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. It is a key target for the treatment of endocrine and metabolic disorders, such as Cushing's syndrome, Addison's disease, and adrenal insufficiency. ACTHR agonists and antagonists are used to modulate the activity of the HPA axis, and can be used to treat a variety of endocrine and metabolic disorders. Several pharmaceutical companies are involved in the development of ACTHR-targeted drugs. These include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more